Scaling Human Biology: Mariana Argenziano's Impact on iPSC Manufacturing

Published on January 20, 2026

When Mariana Argenziano joined Ncardia, the potential of induced pluripotent stem cells was already well understood in drug discovery. What remained unresolved was whether these models could be produced with the consistency and control required to support real development decisions. As Associate Director of Manufacturing, that challenge defines her work. 

Continue reading on website
Other news

PharmTech: Industry Outlook 2026- The Impact of Novel Therapies

January 15, 2026
Each year, as part of PharmTech’s preparation for the new year, the editors speak with experts in the industry to find out which trends happened in the past year that they think impacted the industry the most and will, they believe, continue into the new year. Campbell Bunce, chief scientific officer at Abzena, pointed to two trends in 2025 that stood out: the influx of novel therapies and onshori

Manufacturing Chemist: How early data drives better cell line development

January 20, 2026
In the race to bring new biologics to market, development teams are constantly balancing speed, quality and regulatory expectations. Yet one factor often determines long-term success more than any other: the strength of the data generated in the earliest phases of cell line development.Meticulous records of clonality, phenotypic stability and quality control do more than simply satisfy regulators.